Investigation of outcome measures and anomalous lower extremity in osteoarthritis patients with Jumpstart nutrition® supplementation

Abstract

Background: Osteoarthritis (OA) is characterized by cartilage and synovial inflammation as well as anomalous lower extremity leading to joint pain, and impairment in lifestyle and epidemic of obesity. This study aimed to use the Jumpstart Nutrition® supplement (JNS) for achieving symmetry of aberrant lower extremity and improving the outcome measures in the management of OA.

Methods: This week-twelve registry included 108 patients treated with JNS mainly comprised of calcium, phosphorus, magnesium, vitamin-K₂, coenzyme-Q₁₀, vitamin-C, boswellic acids, and curcumin mixed with soy and whey proteins (experimental group) and 72 were treated with symptomatic slow-acting drugs (control group) for chronic OA confirmed with radiological images. The outcome measures (Visual analogue scale, Western Ontario and McMaster Universities Osteoarthritis Index, Knee-injury Osteoarthritis Outcomes Scale, and Body mass index), and anomalous lower extremity included bilateral: knee gaps between biceps femoris-short head and surface of the bed, diameters of muscles at the calf, the thigh, 4cm above and below the patella, angles of straight leg raising, knee- flexion and-extension in supine were evaluated with appropriate protocol at week-0 and at week-12 for both the groups.

Results: After week-12, risk ratios of studied lower extremity, and mean ±standard deviation of all outcome measures were significantly improved (p<0.0001), and Kellgren-Lawrence scale (KLS) was upgraded to ≥2 in experimental group compared to control.

Conclusions: This registry study indicates that JNS can be used to achieve symmetry of studied lower extremity and to improve the outcome measures safely as an effective management of OA patients confirmed with radiological images correlated with KLS.

Keywords: Aberrant outcome measures; Abnormal lower extremity; Dietary supplement; Osteoarthrosis; Symptomatic slow-acting drugs..

Figure 1

Study flow chart according to Consolidated Standards of Reporting Trials (CONSORT)

Figure 2

Classification of age groups (45-55, 56-65 and 66-75 years) of 108 experimental patients, 36male-only and 72female-only using Jumpstart Nutrition® supplement

Figure 3

Classification of age groups (45-55, 56-65 and 66-75 years) of 72 control patients, 27 male-only and 45 female-only without using Jumpstart Nutrition® supplement

Figure 4

ROC Curves for lower extremity Experimental group (n=108)-vs-Control Group (n=72)

Figure 5

Risk Ratio of lower extremities of 108 subjects, (female: 72 and male: 36), using Jumpstart Nutrition® Supplement compared to 72 control subjects (female: 45 and male: 27) at week twelve.

Figure 6

Risk Ratio of outcome measures of 108 subjects, (female: 72 and male: 36), using Jumstart Nutrition® Supplement compared to 72 control subjects (female: 45 and male:27) at week twelve

Figure 7

ROC curves for body mass index (BMI) Experimental group (female: 72 and male: 36) vs Control group (female: 45 and male: 27(

Figure 8

Radiological images of the patients with OA before and after the treatment with Jumpstart Nutrition® supplement at week 12